Clinical Trials Logo

Colorectal Tumors clinical trials

View clinical trials related to Colorectal Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03377361 Active, not recruiting - Colorectal Cancer Clinical Trials

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

CheckMate 9N9
Start date: February 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.

NCT ID: NCT01675128 Active, not recruiting - Clinical trials for Colorectal Neoplasms

ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer

Start date: August 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Background: - Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the DNA of growing cancer cells. It is most often used with other chemotherapy drugs. Researchers want to test it with an experimental drug, ISIS 183750. They want to see if the drugs are a safe and effective treatment for advanced solid tumors or colorectal cancer that has not responded to other treatments. Objectives: - To test the safety and effectiveness of ISIS 183750 with irinotecan for advanced solid tumors or colorectal cancer. Eligibility: - Individuals at least 18 years of age who have solid tumors or colorectal cancer that has not responded to other treatments. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will also be collected. Tumor tissue samples may be collected as well before and after treatment. Imaging studies will also be performed. - Participants will take ISIS 183750 once a week for 28-day cycles of treatment. On the first cycle, they will also have ISIS 183750 on days 3 and 5. - Participants will take irinotecan every second week, beginning on day 15 of the first cycle. - Treatment will be monitored with frequent blood tests and imaging studies. - Treatment will continue as long as the cancer does not grow and the side effects are not severe.